Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics

Febuxostat, a drug recently approved in the US, European Union and Japan for treatment of gout, inhibits xanthine oxidoreductase (XOR)-mediated generation of uric acid during purine catabolism. It inhibits bovine milk XOR with a K(i) in the picomolar-order, but we found that it is a much weaker inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Hiroto, Fujisaki, Hiroshi, Furuta, Tadaomi, Okamoto, Ken, Leimkühler, Silke, Nishino, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311054/
https://www.ncbi.nlm.nih.gov/pubmed/22448318
http://dx.doi.org/10.1038/srep00331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3311054/
https://www.ncbi.nlm.nih.gov/pubmed/22448318
http://dx.doi.org/10.1038/srep00331

Ejemplares similares